A few months ago, a founder I advise, let's call her Priya, was stuck in a pattern that may sound familiar to a lot of you.

Priya is a brilliant scientist with a PhD in molecular biology, postdoc at a top-5 cancer center, and a first author on the paper that led to the company's core IP.

She understood her science better than anyone. And she'd poured that understanding into a 27-slide pitch deck - every mechanism explained, every data point contextualized, every competitive nuance accounted for.

The deck was her main calling card. She was sending it in cold emails, warm intros, LinkedIn messages, you name it.

The response, was frustratingly, mostly silence. Maybe a few polite meetings at RESI last year.

When we got on a call, Priya was frustrated, but not in the way you might expect.

She wasn't upset about the rejections. She was upset because she felt like investors weren't even seeing the science.

"They're not making it past slide 3," she told me.

"I can tell from the questions they ask… when they ask anything at all. They're not getting to the data that actually matters."

"What if you sent a one-pager instead?" I suggested.

She pushed back hard - and I get it.

For a technical founder, compressing years of research into a single page feels like a betrayal of the work.

Priya's exact words were: "If I cut the MOA section, they won't understand why our approach is different. If I cut the competitive landscape, they'll think we're just another me-too. I can't fit what makes us special on one page."

That fear is real, and it's one I hear constantly. There's this deeply held belief that if the investor doesn't see the full picture of the science, they'll miss what makes you special.

That less detail means less credibility. That simplifying equals dumbing down.

But here's what was actually happening: Priya was sending a nearly 30-slide deep dive to people who hadn't yet decided whether to spend 30 seconds on her company.

She was answering questions nobody had asked - yet, and in doing so, she was burying the signal in the noise.

We spent an afternoon rebuilding her story into a single page. She agonized over what to cut. She hated the first three versions.

But by version four, something clicked - the one-pager didn't dilute her story. It sharpened it.

She sent it to an investor the following Tuesday through a warm intro. By Thursday, she had a meeting on the calendar.

In the meeting, the investor told her: "Your one-pager was the clearest summary I've seen this quarter. Let’s dig into the details."

That's the misunderstanding that I see most often.

The one-pager isn't a lesser version of your deck. It's the document that earns the right to present it.

The science that Priya was so afraid of losing? It all came through in the meeting - because she actually got in the room.

If you already have a pitch deck and a company blurb, you might be wondering: Do I really need a one-pager too? And if I have one, do I send it with the deck? What's even the point?

I get some version of this question almost every week. So let me clear it up.

Your blurb, your one-pager, and your deck are three different tools that serve three different moments in the investor relationship.

Your blurb is your verbal introduction - the 60-second answer to "what does your company do?"

Your deck is the full story you present in a meeting.

Your one-pager sits in between: it's the document that earns the meeting.

Here's when the one-pager is the right move - and when it's not.

You're making a cold or warm intro.

Whether you're emailing an investor directly or a mutual contact is forwarding your materials, the one-pager is the appropriate first document.

And when someone makes an intro on your behalf, a one-pager makes it effortless for them - they can forward it with a quick note and the investor can decide in 90 seconds whether to take the meeting.

The lower the friction for your introducer, the more likely they actually send that email.

You're following up after a conference conversation.

You met an investor at JPM, BIO, or ASCO. You had a solid 3-minute hallway chat. They said "send me something."

The one-pager is that something. It matches the energy of a brief interaction.

Most founders rush to send everything… the full deck, team bios, science deep dive - and accidentally turn a warm 'send me something' into a to-do item that sits in the investor inbox and gets procrastinated on.

The goal is to channel that hallway energy into a meeting, not to give them a reason to delay.

An investor specifically requests one.

More common than you'd think. Many VCs, especially at the initial screening stage, ask for a one-pager or executive summary before they'll look at a deck. Having one ready signals you've done this before.

Your champion at the fund needs to sell you internally.

This is the use case founders almost never think about. The associate or partner who likes your company needs to pitch you to their colleagues at the Monday deal review meeting.

Most likely, they won’t have the time to walk through a 20 slide deck. They're pulling up a single page and saying "here's why I think we should get involved."

If you haven't given them that document, they're writing it themselves. And they may not do your story justice.

You're talking to angels or family offices outside biotech.

Non-specialist investors are evaluating across sectors. They don't have the bandwidth or the background for a 15-slide biotech deck on the first pass.

A one-pager that clearly communicates the opportunity in plain language gets you much further than leading with the science.

Your board members or advisors want to share deal flow.

When your existing investors or advisors want to refer you to someone in their network, the one-pager is the asset they'll actually forward.

Think of it as the "shareable unit" of your fundraise - the thing that travels through networks on your behalf when you're not in the room.

You're building relationships before a raise.

If you're 6-12 months out from fundraising and want to get on investors' radar early, a one-pager with a "not raising yet, but here's what we're building" framing is the right touch.

A full deck at that stage creates awkward timing conversations and can burn a first impression before you're ready.

You're applying to accelerators or grants.

Many programs ask for a brief company summary alongside the application. A polished one-pager means you're not scrambling to compress your deck the night before a deadline.

Not every situation calls for a one-pager. The deck is the right tool when the relationship has already progressed past the "should we talk?" stage.

The investor has already agreed to a meeting.

Once you're on someone's calendar, the deck is what you present. Some investors want it in advance to prepare; others prefer to see it live. Either way, this is what the meeting runs on, not the one-pager.

You've had a substantive in-person conversation and they "get it."

If you spent 20 minutes at a conference going deep on your science and the investor said, "send me your deck," trust them.

They've already been sold on the concept - now they want the details. Sending a one-pager at this point would feel like a step backward.

You're in active conversations.

Once an investor is evaluating your company seriously, they need the complete picture: team slides, competitive landscape, financial projections, development timeline. The one-pager has done its job - it got you here.

A trusted advisor or investor offers to make a strong intro and asks for the deck.

If someone with a close relationship to the target investor says "send me your deck, I'll walk them through it," let them. They're essentially volunteering to give your pitch for you. Give them the full ammunition.

You're presenting at a pitch event or demo day.

These are structured presentations with allocated time. The deck is the format. (Though having a one-pager as a leave-behind for the audience is a smart move).

You're engaging pharma BD or corporate venture teams.

These teams are built to evaluate decks - it's their native format. BD teams screen hundreds of opportunities through internal processes designed around slide decks and data packages, and typically not one-pagers.

Corporate venture arms work the same way. They're not deciding whether to just take a meeting - they're evaluating whether your science fits their pipeline, and they need the detail a deck provides.

(One exception: if you had a quick hallway chat at a conference, a one-pager follow-up can work well as a bridge before they loop in their team).

If you're trying to get the meeting → one-pager. If you're in the meeting → deck.

When in doubt, lead with the one-pager. You can always follow up with the deck. You can never un-send a 27-slide attachment that someone didn't ask for.

Now let's talk about how to build a one-pager that actually works.

Think of your one-pager as an investor's first filter. They're not reading it to make an investment decision; they're reading it to decide whether to give you 30 minutes.

Here's the framework I use when reviewing one-pagers with founders I advise:

This is the single sentence at the top that tells the investor what you do and why it matters. Not your company name. Not your technology platform.

The outcome your science enables.

Bad: "XenoBio is a preclinical-stage biotech developing novel small molecule inhibitors of the XYZ pathway."

Better: "Turning treatment-resistant pancreatic cancer into a manageable disease - with a first-in-class oral therapy entering IND-enabling studies."

The headline should pass the "cocktail party test" - would a smart non-scientist understand why this matters? If it reads like an abstract, rewrite it.

This should be 2-3 sentences. What's broken in the current standard of care, and who suffers?

Ground it in numbers if you can: patient population size, mortality rates, failure rates of current treatments, cost burden.

Investors need to feel the weight of the problem before they care about your solution. This is where you create urgency without being hyperbolic.

Three to four sentences maximum. What is your technology, and what makes it differentiated? This is where technical founders tend to over-explain. Resist the urge.

Rule of thumb: describe the what and the so what, not the how.

"Our proprietary mRNA delivery platform achieves 10x greater tumor penetration than current lipid nanoparticle approaches" is better than three paragraphs about your formulation chemistry.

If your mechanism of action matters (and in biotech it usually does), one clear sentence is enough. Save the deep science for the deck.

This is the section that separates compelling one-pagers from forgettable ones. Include two to four proof points that demonstrate your science works and your company is making progress.

These can include:

Present these as crisp bullet points or a mini data table. No paragraphs. Let the numbers speak.

Two to three sentences framing the commercial potential. Total addressable market, but, more importantly, the serviceable market you're targeting first.

Investors are skeptical of "Massive $500B TAM" claims.

They're more interested in: "The frontline treatment market for this indication is $3.2B and growing at 12% annually, with no approved targeted therapy."

If you can reference a comparable transaction (acquisition, licensing deal, or IPO in your space), include it. This is the research that investors will be doing after looking at your document.

Two to three lines. Not full bios - just names, titles, and the single most relevant credential for each person. The goal is to answer: "Are these the right people to pull this off?"

For a therapeutics company, the investor wants to see: relevant scientific expertise, drug development experience, and ideally someone who's done this before (built a company, run a clinical program, navigated an exit).

If you have a notable advisor or board member, one line is enough.

One to two sentences. What are you raising, and what will it fund? Be specific about the milestone the capital gets you to.

"Raising a $3M seed round to complete IND-enabling studies and file our IND by Q4 2026" is clear and fundable. "Raising capital to advance our pipeline" is not.

If you're not actively fundraising but want the meeting anyway, frame it as: "Currently exploring strategic partnerships and preparing for a Series A raise in [timeframe]." This still gives the investor a reason to engage.

The difference between a one-pager that gets a meeting and one that gets ignored usually comes down to three things:

Clarity over completeness. Your one-pager doesn't need to answer every question - it needs to make the investor want to ask questions. If you're cramming text into every margin, you've lost the plot.

Investor-first language. Write for the person reading it, not for your scientific advisory board. Every sentence should either build confidence in the opportunity or create curiosity about the details.

Visual breathing room. White space isn't wasted space. A one-pager that feels airy and scannable gets read. A wall of 9-point text gets shelved and forgotten.

Content Check:

□ Headline passes the cocktail party test - a smart non-scientist gets it

□ Problem section uses at least one concrete number (patient population, cost, failure rate)

□ Solution section is 4 sentences or fewer - describes the what and so what, not the how

□ Includes 2-4 specific data points or validation milestones

□ Market section references a specific, credible market size with a source or comparable

□ Team section highlights relevant credentials, not full CVs

□ Ask is specific: dollar amount + milestone it funds + timeline

Design & Readability Check:

□ Fits on exactly one page (no cheating with tiny fonts)

□ Font is 10pt minimum (preferably 11pt)

□ At least 20-25% white space

□ Company logo and contact info are present but not dominant

□ A non-biotech friend can read it in under 90 seconds and explain what you do

The "Send" Test:

□ You'd be comfortable if this landed on a top-tier VC's desk tomorrow

□ It makes someone want to learn more, not feel like they already know everything

□ You've had at least one person outside your company review it

Copy these into ChatGPT, Claude, or your AI tool of choice. Replace the bracketed sections with your details or upload a copy of your non-confidential deck.

Prompt #1: Generate Your Headline

Prompt #2: Draft Your Problem Section

Prompt #3: One-Pager Self-Review

Your deck and your one-pager are a team. One tells the full story. The other earns the right to tell it. Most founders skip the second one, and wonder why they're not getting meetings.

One caveat: this isn't a one-size-fits-all playbook. Some investors, especially those with deep technical backgrounds, genuinely prefer to dig into a 30-page deck on a first read.

That's a character read you'll develop over time. But for 80-90% of situations, the guidance in this newsletter will serve you well.

So, open a blank doc this weekend. Develop one headline, one problem, one solution. A few proof points. A clear ask.

You might be surprised how much sharper your story gets when you give it less room to hide.

If this was helpful, hit reply and let me know.

Already have a one-pager and not sure if it's landing? Been sending your deck cold and getting silence? Let me know, I'd love to help.

Know a founder who needs to hear this? Forward it their way.

Until next week!

- Vadim

PS: When you’re ready, here’s how I can help:

PPS: I'm building something to make one-pagers a lot easier. I'll be including Canva templates, examples across therapeutics, diagnostics, and platform companies, and step-by-step video walkthroughs. More details coming soon - stay tuned! (And if you have things you’d like to see, reply to this email and let me know!)